Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Inclusion Criteria

• •Participant or legally authorized representative (LAR) must provide written informed consent before any study-specific procedures or interventions are performed
• •In consultation with principal investigator (PI) and treating physician, participant's cancer-directed therapy allows for a 1-day period between administration of study drug and subsequent start of planned cancer-directed therapy
• •Individuals with a confirmed solid malignancy that are scheduled to undergo insertion of a PICC line or indwelling central venous catheter as part of planned anticancer therapy per institutional standards
• •Must have Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
• •Platelet count \> 100 x 10\^9/L
• •Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Participants of childbearing potential are defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal
• •Female participants of childbearing potential must agree to use adequate methods of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy. Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year without an alternative medical cause
• •Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy
• •Previously documented hypersensitivity to either the drug or excipients
• •Psychiatric illness/social situations, or any other condition, that in the opinion of the investigator, would limit compliance with study requirements
• •Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 90 days after the last dose of trial treatment
• •Participant is allergic to heparin or heparin derivatives
• •Participants with a history of venous thromboembolism within the last 3 months